Phase 2 Study to Evaluate RPT193 in Adults With Moderate to Severe T2-high Asthma

Summary

Randomized, multi-center, double-blind, placebo-controlled, parallel group, proof of-concept study with RPT193 in subjects with T2-high, moderate-to-severe asthma who are partially controlled on medium or high doses of inhaled corticosteroids (ICS) in combination with long-acting beta 2 agonist (LABA).

Timeline

Start

2023-07-05

Primary completion

2024-06-21

Completion

2024-06-21

Outcome

Outcome not reported

Stopped: “Study on clinical hold by FDA”

Drugs

Indications